Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 1Sarcoma 1Dermatologic 1Breast 1

Conditions

Sarcoma 13Melanoma 5Lung Neoplasms 3Breast Neoplasms 3Sarcoma, Synovial 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Desmoplastic Small Round Cell Tumor 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bone Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma, Endometrial Stromal 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1Liposarcoma 1

Interventions

Filgrastim 4Carboplatin 4Thiotepa 3pembrolizumab 2ixabepilone 2Temozolomide 2Riluzole 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Oncolytic Virotherapy 2Melphalan 2Ipilimumab 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Drug Therapy 2Cyclophosphamide 2Busulfan 2trastuzumab deruxtecan 1spartalizumab 1sodium thiosulfate 1sargramostim 1pazopanib 1fludarabine 1etoposide phosphate 1Topotecan 1Thrombopoietin 1Tamoxifen 1Stem Cell Transplantation 1Restraint, Physical 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × Injections × Sarcoma × Clear all
NCT00041808 2005-06-24

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

FeRx

Phase 1/2 Completed
20 enrolled
BreastDermatologicGastrointestinalSarcomaThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡